Welcome to our dedicated page for NewAmsterdam Pha news (Ticker: namsw), a resource for investors and traders seeking the latest updates and insights on NewAmsterdam Pha stock.
NewAmsterdam Pharma (NAMSW) is a clinical-stage biopharmaceutical company advancing obicetrapib, a novel oral CETP inhibitor targeting LDL cholesterol reduction in high-risk cardiovascular patients. This news hub provides investors and healthcare professionals with essential updates on clinical milestones, regulatory developments, and strategic initiatives.
Access timely announcements about ongoing Phase 3 trials (BROOKLYN, BROADWAY, PREVAIL), partnership agreements, and intellectual property advancements. Our curated news collection serves as a centralized resource for tracking obicetrapib's progress through late-stage development and potential commercialization.
Key updates include trial result disclosures, FDA/EMA regulatory communications, manufacturing partnerships, and peer-reviewed publication highlights. All content is verified through primary sources to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for direct access to NewAmsterdam's latest press releases and objective updates about their cardiovascular pipeline. Monitor critical developments in lipid management therapeutics through our maintained news archive.
NewAmsterdam Pharma has completed patient enrollment in the pivotal Phase 3 BROOKLYN clinical trial for obicetrapib, targeting adult patients with heterozygous familial hypercholesterolemia (HeFH) whose LDL-C levels are inadequately managed despite maximal lipid-lowering therapy. The trial enrolled 354 participants across ten countries, with results expected in the second half of 2024. Obicetrapib, a next-generation CETP inhibitor, aims to offer improved options for HeFH patients. Previous Phase 2 trials showed significant LDL-C reduction of 51% and 59% in combination therapy. The rapid enrollment reflects a pressing unmet need for effective LDL-C management in the HeFH community.
FAQ
What is the current stock price of NewAmsterdam Pha (namsw)?
